Juan Carlos Núñez-Enríquez1, Diego Alberto Bárcenas-López2, Alfredo Hidalgo-Miranda2, Elva Jiménez-Hernández3, Vilma Carolina Bekker-Méndez4, Janet Flores-Lujano1, Karina Anastacia Solis-Labastida5, Gabriela Bibiana Martínez-Morales1, Fausto Sánchez-Muñoz6, Laura Eugenia Espinoza-Hernández3, Martha Margarita Velázquez-Aviña7, Laura Elizabeth Merino-Pasaye8, Alejandra Jimena García Velázquez9, María Luisa Pérez-Saldívar1, Raúl Mojica-Espinoza10, Julián Ramírez-Bello11, Silvia Jiménez-Morales12, Juan Manuel Mejía-Aranguré13. 1. Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. 2. Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico. 3. Servicio de Hematología Pediátrica, Hospital General "Gaudencio González Garza", Centro Médico Nacional (CMN) "La Raza", IMSS, Mexico City, Mexico. 4. Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología "Dr. Daniel Méndez Hernández", "La Raza", IMSS, Mexico City, Mexico. 5. Servicio de Hematología Pediátrica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. 6. Departamento de Inmunología, Instituto Nacional de Cardiología "Ignacio Chávez" (INCICh), Mexico City, Mexico. 7. Servicio de Onco-Pediatria, Hospital Juárez de México, Secretaria de Salud (SSa), Mexico City, Mexico. 8. Servicio de Hematología Pediátrica, Centro Médico Nacional (CMN) "20 de Noviembre", Instituto de Seguridad Social al Servicio de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico. 9. Servicio de Oncología, Hospital Pediátrico de Moctezuma, Secretaría de Salud del D.F., Mexico City, Mexico. 10. Unidad de Genotipificación y Análisis de Expresión, Instituto Nacional de Medicina Genómica, Mexico City, Mexico. 11. Unidad de Investigación de Enfermedades Metabólicas y Endócrinas, Hospital Juárez de México, Mexico City, Mexico. 12. Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico. Electronic address: sjimenez@inmegen.gob.mx. 13. Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional (CMN) "Siglo XXI", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. Electronic address: juan.mejiaa@imss.gob.mx.
Abstract
BACKGROUND AND AIMS: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer worldwide. Mexican patients have high mortality rates, low frequency of good prognosis biomarkers (i.e., ETV6-RUNX1) and a high proportion is classified at the time of diagnosis with a high risk to relapse according to clinical features. In addition, very early relapses are more frequently observed than in other populations. The aim of the study was to identify new potential biomarkers associated with very early relapse in Mexican ALL children through transcriptome analysis. METHODS: Microarray gene expression profiling on bone marrow samples of 54 pediatric ALL patients, collected at time of diagnosis and/or at relapse, was performed. Eleven patients presented relapse within the first 18 months after diagnosis. Affymetrix Human Transcriptome Array 2.0 (HTA 2.0) was used to perform gene expression analysis. Annotation and functional enrichment analyses were carried out using Gene Ontology, KEGG pathway analysis and Ingenuity Pathway Analysis tools. RESULTS: BLVRB, ZCCHC7, PAX5, EBF1, TMOD1 and BLNK were differentially expressed (fold-change >2.0 and p value <0.01) between relapsed and non-relapsed patients. Functional analysis of abnormally expressed genes revealed their important role in cellular processes related to the development of hematological diseases, cancer, cell death and survival and in cell-to-cell signaling interaction. CONCLUSIONS: Our data support previous findings showing the relevance of PAX5, EBF1 and ZCCHC7 as potential biomarkers to identify a subgroup of ALL children in high risk to relapse.
BACKGROUND AND AIMS: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer worldwide. Mexican patients have high mortality rates, low frequency of good prognosis biomarkers (i.e., ETV6-RUNX1) and a high proportion is classified at the time of diagnosis with a high risk to relapse according to clinical features. In addition, very early relapses are more frequently observed than in other populations. The aim of the study was to identify new potential biomarkers associated with very early relapse in Mexican ALL children through transcriptome analysis. METHODS: Microarray gene expression profiling on bone marrow samples of 54 pediatric ALL patients, collected at time of diagnosis and/or at relapse, was performed. Eleven patients presented relapse within the first 18 months after diagnosis. Affymetrix Human Transcriptome Array 2.0 (HTA 2.0) was used to perform gene expression analysis. Annotation and functional enrichment analyses were carried out using Gene Ontology, KEGG pathway analysis and Ingenuity Pathway Analysis tools. RESULTS:BLVRB, ZCCHC7, PAX5, EBF1, TMOD1 and BLNK were differentially expressed (fold-change >2.0 and p value <0.01) between relapsed and non-relapsed patients. Functional analysis of abnormally expressed genes revealed their important role in cellular processes related to the development of hematological diseases, cancer, cell death and survival and in cell-to-cell signaling interaction. CONCLUSIONS: Our data support previous findings showing the relevance of PAX5, EBF1 and ZCCHC7 as potential biomarkers to identify a subgroup of ALL children in high risk to relapse.
Authors: Bin Xiao; Jiaying Li; Mengsi Zhou; Xiaoqing Li; Xiaoyan Huang; Jianfeng Hang; Zhaohui Sun; Linhai Li Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2019-02-28
Authors: Didier Ismael May-Hau; Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Vilma Carolina Bekker-Méndez; Fredy Omar Beltrán-Anaya; Elva Jiménez-Hernández; Mónica Patricia Ortíz-Maganda; Francisco Xavier Guerra-Castillo; Aurora Medina-Sanson; Janet Flores-Lujano; Jorge Alfonso Martín-Trejo; José Gabriel Peñaloza-González; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; Gabriela Alicia Hernández-Echáurregui; Rosa Martha Espinosa-Elizondo; María de Lourdes Gutiérrez-Rivera; Rodrigo Sanchez-Hernandez; María Luisa Pérez-Saldívar; Luz Victoria Flores-Villegas; Laura Elizabeth Merino-Pasaye; David Aldebarán Duarte-Rodríguez; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Haydeé Rosas-Vargas; Alfredo Hidalgo-Miranda; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738
Authors: Daniel Castillo; Juan Manuel Galvez; Luis J Herrera; Fernando Rojas; Olga Valenzuela; Octavio Caba; Jose Prados; Ignacio Rojas Journal: PLoS One Date: 2019-02-12 Impact factor: 3.240
Authors: Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Alfredo Hidalgo-Miranda; Fredy Omar Beltrán-Anaya; Didier Ismael May-Hau; Elva Jiménez-Hernández; Vilma Carolina Bekker-Méndez; Janet Flores-Lujano; Aurora Medina-Sansón; Edna Liliana Tamez-Gómez; Víctor Hugo López-García; José Ramón Lara-Ramos; Nora Nancy Núñez-Villegas; José Gabriel Peñaloza-González; Luz Victoria Flores-Villegas; Raquel Amador-Sánchez; Rosa Martha Espinosa-Elizondo; Jorge Alfonso Martín-Trejo; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; María Luisa Pérez-Saldívar; David Aldebarán Duarte-Rodríguez; José Refugio Torres-Nava; Beatriz Cortés-Herrera; Karina Anastacia Solís-Labastida; Ana Itamar González-Ávila; Jessica Denisse Santillán-Juárez; Alejandra Jimena García-Velázquez; Haydee Rosas-Vargas; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales Journal: Genes (Basel) Date: 2020-03-13 Impact factor: 4.096